蔗糖铁注射液治疗血液透析患者肾性贫血研究

目的比较静脉滴注蔗糖铁（森铁能）与口服琥珀酸亚铁（速力菲）治疗使用促红细胞生成素（EPO）的维持性血液透析（MHD）患者肾性贫血的疗效与安全性。方法将64例血液透析患者随机分为静脉组（32例）和口服组（32例）。观察并比较两组患者贫血治疗的效果，铁代谢指标变化和不良反应发生情况。结果治疗后两组血红蛋白（Hb）、血清铁蛋白（SF）、红细胞压积（HCT）、血清转铁蛋白饱和度（TSAT）均有升高。静脉组比口服组升高差异有统计学意义（P〈0．05）；静脉组不良反应发生率少于口服组（P〈0．05）；治疗前后两组肝功能、c一反应蛋白（CRP）等生化指标差异无统计学意义。结论静脉蔗糖铁治疗MHD患者肾性贫血的疗效与安全性均优于口服琥珀酸亚铁。

A Clinical Trial of Intravenous Iron Sucrose Rherapy in Anemia Hemo-dialysis Patients

Objective To determine and compare the efficacy and safety of intravenous iron sucrose with oral ferrous succinate in rHuEPO-treated maintenance hemodialysis patients. Methods 64 hemadialysis patients were randomized divided into intravenous iron group（ group A n = 32） ,and oral iron group（ group B n = 32） ,the results of anti-anemia therapy,iron metabolism index and adverse events were observed. Results All the baseline parameters were comparable between two groups. After treatment, hemoglobin, serum ferritin, hematocrit and trasferrin saturation were significantly increased in both groups. However, the increase of these parameters was significantly higher in group A than in group B （ P 〈 0.05 ）. There were less adverse events in group A than in group B （ P 〈 0.05 ）. The liver function and CRP between the two groups anti-or pasHreatment were comparable. Conclusion Intravenous iron sucrose was more effective and safer in treating anemic hemohialysis patients.